

## EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	63168	casein	US-PGPUB; USPAT; USOCR; DERWENT	OR	ON	2006/11/16 10:39
L2	1291	L1 and (tyrosin\$ near5 leucin\$)	US-PGPUB; USPAT; USOCR; DERWENT	OR	ON	2006/11/16 10:41
L3	355	L2 and (\$hypertension)	US-PGPUB; USPAT; USOCR; DERWENT	OR	ON	2006/11/16 10:41
L4	96	L2 and (angiotensin)	US-PGPUB; USPAT; USOCR; DERWENT	OR	ON	2006/11/16 11:13
L5	69	L2 and (ACE)	US-PGPUB; USPAT; USOCR; DERWENT	OR	ON	2006/11/16 11:08
L6	18	L2 and (trypsin near5 hydroly\$)	US-PGPUB; USPAT; USOCR; DERWENT	OR	ON	2006/11/16 10:52
L7	58	L3 and L4	US-PGPUB; USPAT; USOCR; DERWENT	OR	ON	2006/11/16 11:28
L8	27	L3 and L5	US-PGPUB; USPAT; USOCR; DERWENT	OR	ON	2006/11/16 10:49
L9	2	L3 and L6	US-PGPUB; USPAT; USOCR; DERWENT	OR	ON	2006/11/16 10:49
L10	3424	L1 and hypertension	US-PGPUB; USPAT; USOCR; DERWENT	OR	ON	2006/11/16 11:29
L11	0	L1 and (trypsin near5 hydroly\$)	US-PGPUB; USPAT; USOCR; DERWENT	OR	ON	2006/11/16 11:29

## EAST Search History

L12	6207	L1 and (trypsin)	US-PGPUB; USPAT; USOCR; DERWENT	OR	ON	2006/11/16 11:30
L13	17763	L1 and (hydrolys\$)	US-PGPUB; USPAT; USOCR; DERWENT	OR	ON	2006/11/16 11:30
L14	13945	L1 and (hydrolyz\$)	US-PGPUB; USPAT; USOCR; DERWENT	OR	ON	2006/11/16 11:31
L15	3098	L12 and L13	US-PGPUB; USPAT; USOCR; DERWENT	OR	ON	2006/11/16 11:31
L16	2430	L12 and L14	US-PGPUB; USPAT; USOCR; DERWENT	OR	ON	2006/11/16 11:31
L17	467	L15 and angiotensin	US-PGPUB; USPAT; USOCR; DERWENT	OR	ON	2006/11/16 11:31
L18	431	L16 and angiotensin	US-PGPUB; USPAT; USOCR; DERWENT	OR	ON	2006/11/16 11:32
L19	154	L17 and @pd<="20030624"	US-PGPUB; USPAT; USOCR; DERWENT	OR	ON	2006/11/16 11:33
L20	135	L18 and @pd<="20030624"	US-PGPUB; USPAT; USOCR; DERWENT	OR	ON	2006/11/16 11:33
L21	117	L19 and (converting adj enzyme)	US-PGPUB; USPAT; USOCR; DERWENT	OR	ON	2006/11/16 11:33
L22	116	L20 and (converting adj enzyme)	US-PGPUB; USPAT; USOCR; DERWENT	OR	ON	2006/11/16 11:34
L23	103	L21 and L22	US-PGPUB; USPAT; USOCR; DERWENT	OR	ON	2006/11/16 11:34

US 20060193962 A1 US-PGPUB  
US 20060084057 A1 US-PGPUB  
US 20040203134 A1 US-PGPUB  
US 20040161478 A1 US-PGPUB  
US 20030175686 A1 US-PGPUB  
US 6986995 B2 USPAT  
US 6296847 B1 USPAT  
US 6153592 A USPAT  
US 5861477 A USPAT  
US 5814460 A USPAT  
US 5780439 A USPAT  
US 5759834 A USPAT  
US 5541098 A USPAT  
US 5382518 A USPAT  
US 5366862 A USPAT  
US 5116615 A USPAT  
US 4186188 A USPAT  
US 2835592 A USOCR

US 20060216727 A1	US-PGPUB	US 5876756 A	USPAT
US 20060153801 A1	US-PGPUB	US 5814460 A	USPAT
US 20060137042 A1	US-PGPUB	US 5530161 A	USPAT
US 7060811 B2	USPAT	US 5514677 A	USPAT
US 7060476 B2	USPAT	US 5366862 A	USPAT
US 20060117401 A1	US-PGPUB	US 5310763 A	USPAT
US 20060110771 A1	US-PGPUB	US 5304604 A	USPAT
US 7045532 B2	USPAT	US 5240958 A	USPAT
US 7041474 B2	USPAT	US 3644617 A	USOCR
US 20060094693 A1	US-PGPUB	US 3576719 A	USOCR
US 7030082 B2	USPAT	US 3515641 A	USOCR
US 20060062786 A1	US-PGPUB	US 3316148 A	USOCR
US 20060024780 A1	US-PGPUB	US 3275453 A	USOCR
US 20050215640 A1	US-PGPUB	US 3111459 A	USOCR
US 20050209223 A1	US-PGPUB		
US 20050186569 A1	US-PGPUB		
US 20050176827 A1	US-PGPUB		
US 20050136032 A1	US-PGPUB		
US 20050123912 A1	US-PGPUB		
US 20050119269 A1	US-PGPUB		
US 20050118582 A1	US-PGPUB		
US 20050113347 A1	US-PGPUB		
US 6858580 B2	USPAT		
US 20050019833 A1	US-PGPUB		
US 20040219188 A1	US-PGPUB		
US 20040171012 A1	US-PGPUB		
US 20040152093 A1	US-PGPUB		
US 6770625 B2	USPAT		
US 20040137448 A1	US-PGPUB		
US 20040121361 A1	US-PGPUB		
US 20040101884 A1	US-PGPUB		
US 20040082496 A1	US-PGPUB		
US 20040053291 A1	US-PGPUB		
US 20040048290 A1	US-PGPUB		
US 20040047894 A1	US-PGPUB		
US 20040043388 A1	US-PGPUB		
US 20040018505 A1	US-PGPUB		
US 20040017387 A1	US-PGPUB		
US 20030228275 A1	US-PGPUB		
US 20030215827 A1	US-PGPUB		
US 20030198610 A1	US-PGPUB		
US 6632934 B1	USPAT		
US 20030172388 A1	US-PGPUB		
US 20030165873 A1	US-PGPUB		
US 20030077329 A1	US-PGPUB		
US 20030069170 A1	US-PGPUB		
US 20030040017 A1	US-PGPUB		
US 20030037350 A1	US-PGPUB		
US 20030017573 A1	US-PGPUB		
US 20030008299 A1	US-PGPUB		
US 20020055139 A1	US-PGPUB		
US 20020037837 A1	US-PGPUB		
US 20020022591 A1	US-PGPUB		
US 6312941 B1	USPAT		
US 20010018075 A1	US-PGPUB		

US 20030109690 A1	US-PGPUB	US 20020132753 A1	US-PGPUB
US 20030108907 A1	US-PGPUB	US 20020119925 A1	US-PGPUB
US 20030108743 A1	US-PGPUB	US 20020119919 A1	US-PGPUB
US 20030103932 A1	US-PGPUB	US 20020107373 A1	US-PGPUB
US 20030096346 A1	US-PGPUB	US 20020102638 A1	US-PGPUB
US 20030096247 A1	US-PGPUB	US 20020094953 A1	US-PGPUB
US 20030092615 A1	US-PGPUB	US 20020091072 A1	US-PGPUB
US 20030092611 A9	US-PGPUB	US 20020090695 A1	US-PGPUB
US 20030092102 A1	US-PGPUB	US 20020090674 A1	US-PGPUB
US 20030092011 A1	US-PGPUB	US 20020090673 A1	US-PGPUB
US 20030082758 A1	US-PGPUB	US 20020090672 A1	US-PGPUB
US 20030082681 A1	US-PGPUB	US 20020090615 A1	US-PGPUB
US 20030077704 A1	US-PGPUB	US 20020086823 A1	US-PGPUB
US 20030077703 A1	US-PGPUB	US 20020086822 A1	US-PGPUB
US 20030077606 A1	US-PGPUB	US 20020086821 A1	US-PGPUB
US 20030077602 A1	US-PGPUB	US 20020086820 A1	US-PGPUB
US 20030068627 A1	US-PGPUB	US 20020086811 A1	US-PGPUB
US 20030059908 A1	US-PGPUB	US 20020086353 A1	US-PGPUB
US 20030059875 A1	US-PGPUB	US 20020086330 A1	US-PGPUB
US 20030054445 A1	US-PGPUB	US 20020077270 A1	US-PGPUB
US 20030054420 A1	US-PGPUB	US 20020068320 A1	US-PGPUB
US 20030054379 A1	US-PGPUB	US 6399349 B1	USPAT
US 20030054377 A1	US-PGPUB	US 20020064856 A1	US-PGPUB
US 20030054375 A1	US-PGPUB	US 6395889 B1	USPAT
US 20030054373 A1	US-PGPUB	US 20020061521 A1	US-PGPUB
US 20030054368 A1	US-PGPUB	US 20020052404 A1	US-PGPUB
US 20030050231 A1	US-PGPUB	US 20020045230 A1	US-PGPUB
US 20030049703 A1	US-PGPUB	US 20020042386 A1	US-PGPUB
US 20030049652 A1	US-PGPUB	US 20020042096 A1	US-PGPUB
US 20030049650 A1	US-PGPUB	US 20020013274 A1	US-PGPUB
US 20030044907 A1	US-PGPUB	US 6331427 B1	USPAT
US 20030044905 A1	US-PGPUB	US 20010047147 A1	US-PGPUB
US 20030044904 A1	US-PGPUB	US 6274718 B1	USPAT
US 20030044890 A1	US-PGPUB	US 6235714 B1	USPAT
US 20030039994 A1	US-PGPUB	US 6127139 A	USPAT
US 20030039993 A1	US-PGPUB	US 6017532 A	USPAT
US 20030027248 A1	US-PGPUB	US 5814460 A	USPAT
US 20030027161 A1	US-PGPUB	US 5811252 A	USPAT
US 6514941 B1	USPAT	US 5543312 A	USPAT
US 20030022338 A1	US-PGPUB	US 5523390 A	USPAT
US 20030013649 A1	US-PGPUB	US 5369015 A	USPAT
US 20020197701 A1	US-PGPUB	US 5366862 A	USPAT
US 20020192800 A1	US-PGPUB	US 5314807 A	USPAT
US 6491672 B2	USPAT	US 5288612 A	USPAT
US 20020182702 A1	US-PGPUB	US 5250414 A	USPAT
US 20020176849 A1	US-PGPUB	US 5243027 A	USPAT
US 20020173640 A1	US-PGPUB	US 5120644 A	USPAT
US 20020173454 A1	US-PGPUB	US 5098887 A	USPAT
US 20020168711 A1	US-PGPUB		
US 20020165137 A1	US-PGPUB		
US 20020164685 A1	US-PGPUB		
US 20020161208 A1	US-PGPUB		
US 20020151479 A1	US-PGPUB		
US 20020147140 A1	US-PGPUB		
US 20020132767 A1	US-PGPUB		

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAHPY1654

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 "Ask CAS" for self-help around the clock  
NEWS 3 AUG 09 INSPEC enhanced with 1898-1968 archive  
NEWS 4 AUG 28 ADISCTI Reloaded and Enhanced  
NEWS 5 AUG 30 CA(SM)/CAplus(SM) Austrian patent law changes  
NEWS 6 SEP 11 CA/CAplus enhanced with more pre-1907 records  
NEWS 7 SEP 21 CA/CAplus fields enhanced with simultaneous left and right  
truncation  
NEWS 8 SEP 25 CA(SM)/CAplus(SM) display of CA Lexicon enhanced  
NEWS 9 SEP 25 CAS REGISTRY(SM) no longer includes Concord 3D coordinates  
NEWS 10 SEP 25 CAS REGISTRY(SM) updated with amino acid codes for pyrrolysine  
NEWS 11 SEP 28 CEABA-VTB classification code fields reloaded with new  
classification scheme  
NEWS 12 OCT 19 LOGOFF HOLD duration extended to 120 minutes  
NEWS 13 OCT 19 E-mail format enhanced  
NEWS 14 OCT 23 Option to turn off MARPAT highlighting enhancements available  
NEWS 15 OCT 23 CAS Registry Number crossover limit increased to 300,000 in  
multiple databases  
NEWS 16 OCT 23 The Derwent World Patents Index suite of databases on STN  
has been enhanced and reloaded  
NEWS 17 OCT 30 CHEMLIST enhanced with new search and display field  
NEWS 18 NOV 03 JAPIO enhanced with IPC 8 features and functionality  
NEWS 19 NOV 10 CA/CAplus F-Term thesaurus enhanced  
NEWS 20 NOV 10 STN Express with Discover! free maintenance release Version  
8.01c now available  
NEWS 21 NOV 13 CA/CAplus pre-1967 chemical substance index entries enhanced  
with preparation role  
  
NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT  
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),  
AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.  
  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items  
NEWS IPC8 For general information regarding STN implementation of IPC 8  
NEWS X25 X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific  
research. Use for software development or design or implementation  
of commercial gateways or other similar uses is prohibited and may  
result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 14:59:43 ON 16 NOV 2006

=> file biosis embase medline  
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FULL ESTIMATED COST

FILE 'BIOSIS' ENTERED AT 15:00:05 ON 16 NOV 2006  
Copyright (c) 2006 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 15:00:05 ON 16 NOV 2006  
Copyright (c) 2006 Elsevier B.V. All rights reserved.

FILE 'MEDLINE' ENTERED AT 15:00:05 ON 16 NOV 2006

=> s angiotensin  
L1 237648 ANGIOTENSIN

=> s L1 and casein  
L2 332 L1 AND CASEIN

=> s L1 and venom peptide  
L3 14 L1 AND VENOM PEPTIDE

=> s L1 and peptide venom  
L4 0 L1 AND PEPTIDE VENOM

=> s L2 and L3  
L5 0 L2 AND L3

=> d L3 1-14 ibib abs

L3 ANSWER 1 OF 14 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN  
ACCESSION NUMBER: 1999:203047 BIOSIS  
DOCUMENT NUMBER: PREV199900203047  
TITLE: Enhancement of bradykinin and resensitization of its B2  
receptor.  
AUTHOR(S): Marcic, Branislav; Deddish, Peter A.; Jackman, Herbert L.;  
Erdos, Ervin G. [Reprint author]  
CORPORATE SOURCE: Department of Pharmacology (M/C 868), University of  
Illinois-Chicago, 835 S Wolcott Ave, Chicago, IL, 60612,  
USA  
SOURCE: Hypertension (Baltimore), (March, 1999) Vol. 33, No. 3, pp.  
835-843. print.  
CODEN: HPRTDN. ISSN: 0194-911X.  
DOCUMENT TYPE: Article  
LANGUAGE: English  
ENTRY DATE: Entered STN: 26 May 1999  
Last Updated on STN: 26 May 1999

AB We studied the enhancement of the effects of bradykinin B2 receptor agonists by agents that react with active centers of angiotensin -converting enzyme (ACE) independent of enzymatic inactivation. The potentiation and the desensitization and resensitization of B2 receptor were assessed by measuring (3H)arachidonic acid release and (Ca2+)i mobilization in Chinese hamster ovary cells transfected to express human ACE and B2 receptor, or in endothelial cells with constitutively expressed ACE and receptor. Administration of bradykinin or its ACE-resistant analogue desensitized the receptor, but it was resensitized (arachidonic acid release or (Ca2+)i mobilization) by agents such as enalaprilat (1 mumol/L). Enalaprilat was inactive in the absence of ACE expression. La3+ (100 mumol/L) inhibited the apparent resensitization, probably by blocking the entry of extracellular calcium. Enalaprilat resensitized the receptor via ACE to release arachidonic acid by bradykinin at a lower concentration (5 nmol/L) than required to mobilize (Ca2+)i (1 mumol/L).

Monoclonal antibodies inhibiting the ACE N-domain active center and polyclonal antiserum potentiated bradykinin. The snake venom peptide BPP5a and metabolites of angiotensin and bradykinin (angiotensin-(1-9), angiotensin-(1-7), bradykinin-(1-8); 1  $\mu\text{mol/L}$ ) enhanced arachidonic acid release by bradykinin. Angiotensin-(1-9) and -(1-7) also resensitized the receptor. Enalaprilat potentiated the bradykinin effect in cells expressing a mutant ACE with a single N-domain active site. Agents that reacted with a single active site, on the N-domain or on the C-domain, potentiated bradykinin not by blocking its inactivation but by inducing crosstalk between ACE and the receptor. Enalaprilat enhanced signaling via ACE by Galphai in lower concentration than by Galphaq-coupled receptor.

L3 ANSWER 2 OF 14 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN  
ACCESSION NUMBER: 1998:265112 BIOSIS  
DOCUMENT NUMBER: PREV199800265112  
TITLE: Isolation: Analysis and properties of three bradykinin-potentiating peptides (BPP-II, BPP-III, and BPP-V) from Bothrops neuwiedi venom.  
AUTHOR(S): Faria-Ferreira, L. A. [Reprint author]; Galle, A.; Raida, M.; Schrader, M.; Lebrun, I.; Habermehl, G.  
CORPORATE SOURCE: Lab. Bioquim. e Biofisica Inst. Butantan, Vital Brasil 1500, Cep. 05503-900 Sao Paulo, SP, Brazil  
SOURCE: Journal of Protein Chemistry, (April, 1998) Vol. 17, No. 3, pp. 285-289. print.  
CODEN: JPCHD2. ISSN: 0277-8033.  
DOCUMENT TYPE: Article  
LANGUAGE: English  
ENTRY DATE: Entered STN: 9 Jun 1998  
Last Updated on STN: 12 Aug 1998

AB In the course of systematic investigations on low-molecular-weight compounds from the venom of Crotalidae and Viperidae, we have isolated and characterized at least three bradykinin-potentiating peptides (BPP-II, BPP-III, and BPP-V) from Bothrops neuwiedi venom by gel filtration on Sephadex G-25 M, Sephadex G-10 followed by HPLC. The peptides showed bradykinin-potentiating action on isolated guinea-pig ileum, for which the BPP-V was more active than of BPP-II, and BPP-III, rat arterial blood pressure, and a relevant angiotensin-converting enzyme (ACE) competitive inhibiting activity. The kinetic studies showed a  $K_i$  of the order of  $9.7 \times 10^{-3} \mu\text{M}$  to BPP-II,  $7 \times 10^{-3} \mu\text{M}$  to BPP-III, and  $3.3 \times 10^{-3} \mu\text{M}$  to BPP-V. The amino acid sequence of the BPP-III has been determined to be pGlu-Gly-Gly-Trp-Pro-Arg-Pro-Gly-Pro-Glu-Ile-Pro-Pro, and the amino acid compositions of the BPP-II and BPP-V by amino acid analysis were 2Glu-2Gly-1Arg-4Pro-1Ile and 2Glu-2Gly-1Ser-3Pro-2Val-1Ile, with molecular weight of 1372, 1046, and 1078, respectively.

L3 ANSWER 3 OF 14 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN  
ACCESSION NUMBER: 1993:385110 BIOSIS  
DOCUMENT NUMBER: PREV199396060410  
TITLE: Mechanism of mastoparan-induced EDRF release from pulmonary artery endothelial cells.  
AUTHOR(S): Tracey, W. Ross [Reprint author]; Peach, Michael J.  
CORPORATE SOURCE: Dep. 46B, Bldg. AP10/2, Abbott Lab., One Abbott Park Road, Abbott Park, IL 60064-3500, USA  
SOURCE: Journal of Vascular Research, (1993) Vol. 30, No. 2, pp. 68-72.  
CODEN: JVREE9. ISSN: 1018-1172.  
DOCUMENT TYPE: Article  
LANGUAGE: English  
ENTRY DATE: Entered STN: 23 Aug 1993  
Last Updated on STN: 3 Jan 1995

AB Mastoparan is a wasp venom peptide that activates G-proteins, certain classes of which are involved in the release of



endothelium-derived relaxing factor (EDRF). In the present study, we investigated whether this peptide might be a useful tool with which to elucidate the signal transduction pathways responsible for EDRF release from pulmonary artery endothelium. Mastoparan (10-50  $\mu$ -g/ml) elicited an increase in endothelial cell cytosolic free calcium concentration ((Ca-2+)-i) and EDRF release in a concentration-dependent manner. Both effects were dependent on Ca-2+ influx, as they were inhibited by removal of extracellular Ca-2+. In addition, when endothelial cells were suspended in Ca-2+-free buffer, mastoparan inhibited ATP-induced increases in (Ca-2+)-i, presumably by depleting intracellular Ca-2+ stores. More importantly, mastoparan also caused the release of fura-2 from dye-loaded endothelial cells, unlike ATP, which did not affect fura-2 loss. These data indicate that although mastoparan may act on G-proteins to elicit release of Ca-2+ from intracellular stores, the primary mechanism of action responsible for mastoparan's ability to elicit EDRF release is an increase in cell membrane permeability followed by an influx of extracellular Ca-2+.

L3 ANSWER 4 OF 14 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN  
ACCESSION NUMBER: 1991:207646 BIOSIS  
DOCUMENT NUMBER: PREV199191110871; BA91:110871  
TITLE: PRODUCTION OF ANGIOTENSIN-CONVERTING ENZYME  
INHIBITORS FROM BAKER'S YEAST GLYCERALDEHYDE-3-PHOSPHATE  
DEHYDROGENASE.  
AUTHOR(S): KOHAMA Y [Reprint author]; NAGASE Y; OKA H; NAKAGAWA T;  
TERAMOTO T; MURAYAMA N; TSUJIBO H; INAMORI Y; MIMURA T  
CORPORATE SOURCE: FAC PHARM SCI, OSAKA UNIV, YAMADAOKA 1-6, SUITA, OSAKA 565,  
JPN  
SOURCE: Journal of Pharmacobio-Dynamics, (1990) Vol. 13, No. 12,  
pp. 766-771.  
CODEN: JOPHDQ. ISSN: 0386-846X.  
DOCUMENT TYPE: Article  
FILE SEGMENT: BA  
LANGUAGE: ENGLISH  
ENTRY DATE: Entered STN: 2 May 1991  
Last Updated on STN: 3 May 1991

AB Angiotensin-converting enzyme (ACE) inhibitors were excised from the molecule of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) preparation of baker's yeast by heating at 120° C in 1 M AcOH-20 mM HCl. Three inhibitors were then purified by gel-permeation and reverse-phase chromatographies. One of the yeast ACE inhibitors, YG-3, was GAPDH peptide 79-89 (Pro-Ala-Asn-Leu-Pro-Trp-Gly-Ser-Ser-Asn-Val, IC50: 18  $\mu$ M), and contained the sequence homologous to vertebrate ACE inhibitors (GAPDH peptides 79-86 or 81-88). Other inhibitors, YG-1 (Gly-His-Lys-Ile-Ala-Thr-Phe-Gln-Glu-Arg, IC50: 0.4  $\mu$ M) and YG-2 (Gly-Lys-Lys-Ile-Ala-Thr-Tyr-Gln-Glu-Arg, IC50: 2  $\mu$ M), correspond to amino acid residues 68-77 in two different forms of yeast GAPDH, respectively. Their sequences were quite different from those of the venom peptide family. YG-1 was the most potent ACE inhibitor among yeast and vertebrate GAPDH peptides excised by acid-limited proteolysis. Thus, yeast GAPDH seems to be an excellent source of naturally occurring ACE inhibitors.

L3 ANSWER 5 OF 14 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN  
ACCESSION NUMBER: 1991:3405 BIOSIS  
DOCUMENT NUMBER: PREV199191003405; BA91:3405  
TITLE: BACILLUS-STEARTHERMOPHILUS GLYCERALDEHYDE-3-PHOSPHATE  
DEHYDROGENASE AS A SOURCE OF ANGIOTENSIN  
-CONVERTING ENZYME INHIBITORS.  
AUTHOR(S): KOHAMA Y [Reprint author]; NAKAGAWA T; OKA H; OKUNO Y;  
MIMURA T; TSUJIBO H; INAMORI Y; TSURUTANI R; NAGATA K;  
TOMITA K  
CORPORATE SOURCE: FAC OF PHARMACEUTICAL SCI, OSAKA UNIV, YAMADAOKA 1-6,  
SUITA, OSAKA 565, JAPAN

SOURCE: Agricultural and Biological Chemistry, (1990) Vol. 54, No. 8, pp. 2115-2120.

CODEN: ABCHA6. ISSN: 0002-1369.

DOCUMENT TYPE: Article

FILE SEGMENT: BA

LANGUAGE: ENGLISH

ENTRY DATE: Entered STN: 8 Dec 1990

Last Updated on STN: 9 Dec 1990

AB The more potent inhibitory activity against angiotensin-converting enzyme (ACE) was excised from a glyceraldehyde-3-phosphate dehydrogenase (GAPDH) preparation of *Bacillus stearothermophilus* by heating at 120° C in 1 M AcOH-20 mM HCl, as compared with GAPDH preparations of yeast and pig. Sufficient excision of *B. stearothermophilus* ACE inhibitors required a longer proteolysis time of 60 min. Two inhibitors were then purified by gel-permeation and reverse-phase chromatographies. One of the *B. stearothermophilus* ACE inhibitors, BG-1, was the GAPDH peptide 68-77 (Gly-Lys-Glu-Ile-Ile-Val-Lys-Ala-Glu-Arg, IC<sub>50</sub>: 32 µM). Another inhibitor, BG-2 (Gly-Lys-Met-Val-Lys-Val-Val-Ser-Trp-Tyr, IC<sub>50</sub>: 6 µM), corresponded to GAPDH peptide 304-313. These sequences were quite different from those of vertebrate GAPDH peptides and the venom peptide family with ACE inhibitory activity. BG-2 was found to be a non-competitive type inhibitor, differing from many natural peptide inhibitors. Thus, *B. stearothermophilus* GAPDH seemed to be a good source of new type ACE inhibitors, in addition to the advantages due to its thermophilic property.

L3 ANSWER 6 OF 14 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN

ACCESSION NUMBER: 1989:46466 BIOSIS

DOCUMENT NUMBER: PREV198936023783; BR36:23783

TITLE: EVOLUTION OF ANGIOTENSIN-CONVERTING ENZYME INHIBITORS.

AUTHOR(S): WYVRATT M J [Reprint author]

CORPORATE SOURCE: MERCK SHARP AND DOHME RES LAB, RAHWAY, NJ 07065, USA

SOURCE: Clinical Physiology and Biochemistry, (1988) Vol. 6, No. 3-4, pp. 217-229.

Meeting Info.: SYMPOSIUM ON THE BIOCHEMISTRY OF HYPERTENSION HELD AT THE 11TH ANNUAL MEETING OF THE NATIONAL ACADEMY OF CLINICAL BIOCHEMISTRY, SAN FRANCISCO, CALIFORNIA, USA, JULY 17-18, 1987. CLIN PHYSIOL BIOCHEM. CODEN: CPBIDP. ISSN: 0252-1164.

DOCUMENT TYPE: Conference; (Meeting)

FILE SEGMENT: BR

LANGUAGE: ENGLISH

ENTRY DATE: Entered STN: 27 Dec 1988

Last Updated on STN: 27 Dec 1988

L3 ANSWER 7 OF 14 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 1999107753 EMBASE

TITLE: Enhancement of bradykinin and resensitization of its B2 receptor.

AUTHOR: Marcic B.; Deddish P.A.; Jackman H.L.; Erdos E.G.

CORPORATE SOURCE: Dr. E.G. Erdos, Department of Pharmacology, M/C 868, University of Illinois-Chicago, 835 S Wolcott Ave, Chicago, IL 60612, United States. EGErdos@uic.edu

SOURCE: Hypertension, (1999) Vol. 33, No. 3, pp. 835-843. . Refs: 57

ISSN: 0194-911X CODEN: HPRTDN

COUNTRY: United States

DOCUMENT TYPE: Journal; Article

FILE SEGMENT: 018 Cardiovascular Diseases and Cardiovascular Surgery  
037 Drug Literature Index

LANGUAGE: English

SUMMARY LANGUAGE: English  
ENTRY DATE: Entered STN: 28 Apr 1999  
Last Updated on STN: 28 Apr 1999

AB We studied the enhancement of the effects of bradykinin B2 receptor agonists by agents that react with active centers of angiotensin-converting enzyme (ACE) independent of enzymatic inactivation. The potentiation and the desensitization and resensitization of B2 receptor were assessed by measuring [3H]arachidonic acid release and [Ca2+](i) mobilization in Chinese hamster ovary cells transfected to express human ACE and B2 receptor, or in endothelial cells with constitutively expressed ACE and receptor. Administration of bradykinin or its ACE-resistant analogue desensitized the receptor, but it was resensitized (arachidonic acid release or [Ca2+](i) mobilization) by agents such as enalaprilat (1  $\mu$ mol/L). Enalaprilat was inactive in the absence of ACE expression. La3+ (100/ $\mu$ mol/L) inhibited the apparent resensitization, probably by blocking the entry of extracellular calcium. Enalaprilat resensitized the receptor via ACE to release arachidonic acid by bradykinin at a lower concentration (5 nmol/L) than required to mobilize [Ca2+](i) (1  $\mu$ mol/L). Monoclonal antibodies inhibiting the ACE N-domain active center and polyclonal antiserum potentiated bradykinin. The snake venom peptide BPP5a and metabolites of angiotensin and bradykinin : (angiotensin-[1-9], angiotensin-[1-7], bradykinin-[1-8]; 1  $\mu$ mol/L) enhanced arachidonic acid release by bradykinin. Angiotensin (1-9) and -(1,7) also resensitized the receptor. Enalaprilat potentiated the bradykinin effect in cells expressing a mutant ACE with a single N-domain active site. Agents that reacted with a single active site, on the N-domain or on the C-domain, potentiated bradykinin not by blocking its inactivation but by inducing crosstalk between ACE and the receptor. Enalaprilat enhanced signaling via ACE by G $\alpha$ (i) in lower concentration than by G $\alpha$ (q)-coupled receptor.

L3 ANSWER 8 OF 14 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 82208347 EMBASE  
DOCUMENT NUMBER: 1982208347  
TITLE: Development and design of specific inhibitors of angiotensin-converting enzyme.  
AUTHOR: Cushman D.W.; Cheung H.S.; Sabo E.F.; Ondetti M.A.  
CORPORATE SOURCE: Squibb Inst. Med. Res., Princeton, NJ 08540, United States  
SOURCE: American Journal of Cardiology, (1982) Vol. 49, No. 6, pp. 1390-1394. .  
CODEN: AJCDAG  
COUNTRY: United States  
DOCUMENT TYPE: Journal  
FILE SEGMENT: 037 Drug Literature Index  
018 Cardiovascular Diseases and Cardiovascular Surgery  
029 Clinical Biochemistry  
LANGUAGE: English  
ENTRY DATE: Entered STN: 9 Dec 1991  
Last Updated on STN: 9 Dec 1991

AB Captopril is a remarkably effective new antihypertensive drug designed and developed as a potent and specific inhibitor of angiotensin-converting enzyme, a zinc metallopeptidase that participates in the synthesis of a hypertensive peptide, angiotensin II, and in the degradation of a hypotensive peptide, bradykinin. Earlier studies with a snake venom peptide (teprotride or SQ 20881) that could be administered only by injection demonstrated that specific inhibitors of angiotensin-converting enzyme could be highly effective as antihypertensive drugs, and helped to clarify the specificity and mechanism of action of the enzyme. A hypothetical model of the active center of angiotensin-converting enzyme based on its presumed analogy to the well characterized zinc metallopeptidase carboxypeptidase A was used to guide logical sequential improvements of a weakly active

prototype inhibitor that led eventually to the highly optimized structure of captopril. The hypothetical working model of the active site of angiotensin-converting enzyme used to develop captopril continues to provide a firm basis for development of new types of specific inhibitors of this biologically important enzyme.

L3 ANSWER 9 OF 14 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 80079370 EMBASE  
DOCUMENT NUMBER: 1980079370  
TITLE: Development of specific inhibitors of angiotensin I converting enzyme (kininase II).  
AUTHOR: Cushman D.W.; Cheung H.S.; Sabo E.F.; et al.  
CORPORATE SOURCE: Squibb Inst. Med. Res., Princeton, N.J. 08540, United States  
SOURCE: Federation Proceedings, (1979) Vol. 38, No. 13, pp. 2778-2782. .  
CODEN: FEPRA7  
COUNTRY: United States  
DOCUMENT TYPE: Journal  
FILE SEGMENT: 037 Drug Literature Index  
029 Clinical Biochemistry  
003 Endocrinology  
018 Cardiovascular Diseases and Cardiovascular Surgery  
LANGUAGE: English  
ENTRY DATE: Entered STN: 9 Dec 1991  
Last Updated on STN: 9 Dec 1991

AB Angiotensin I converting enzyme, a zinc-containing dipeptide-releasing carboxypeptidase, may contribute to elevated blood pressure in hypertensive disease via conversion of angiotensin I to angiotensin II or inactivation or bradykinin. The first therapeutically useful inhibitor of this enzyme was a snake venom peptide SQ 20,881 or teprotide (<Glu-Trp-Pro-Arg-Pro-Gln-Ile-Pro-Pro). Studies with venom peptides and their structural analogs have helped to elucidate the specificity and catalytic mechanism of angiotensin I converting enzyme and to reveal its similarity to the well-characterized pancreatic carboxypeptidase A. Clinical studies with teprotide have demonstrated the potential of such converting enzyme inhibitors for use as antihypertensive drugs. Recently, a new series of potent and specific orally active inhibitors of angiotensin I converting enzyme has been developed using a hypothetical model of the active site of this enzyme, based on its presumed similarity to the known active site of carboxypeptidase A. The design of simple nonpeptidic compounds expected to have multifunctional interactions with this putative active site had led to increasingly more potent and specific inhibitors. Captopril or SQ 14,225 (D-3-mercapto-2-methylpropanoyl-L-proline) is an extremely potent competitive inhibitor ( $K(i)=1.7$  nM) that appears to be of great value for use in chronic therapy of human hypertensive disease.

L3 ANSWER 10 OF 14 MEDLINE on STN

ACCESSION NUMBER: 1999182397 MEDLINE  
DOCUMENT NUMBER: PubMed ID: 10082496  
TITLE: Enhancement of bradykinin and resensitization of its B2 receptor.  
AUTHOR: Marcic B; Deddish P A; Jackman H L; Erdos E G  
CORPORATE SOURCE: Departments of Pharmacology, University of Illinois College of Medicine at Chicago, 60612, USA.  
CONTRACT NUMBER: HL-36473 (NHLBI)  
HL-58118 (NHLBI)  
SOURCE: Hypertension, (1999 Mar) Vol. 33, No. 3, pp. 835-43.  
Journal code: 7906255. ISSN: 0194-911X.  
PUB. COUNTRY: United States  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English

FILE SEGMENT: Priority Journals  
ENTRY MONTH: 199904  
ENTRY DATE: Entered STN: 26 Apr 1999  
Last Updated on STN: 26 Apr 1999  
Entered Medline: 13 Apr 1999

AB We studied the enhancement of the effects of bradykinin B2 receptor agonists by agents that react with active centers of angiotensin-converting enzyme (ACE) independent of enzymatic inactivation. The potentiation and the desensitization and resensitization of B2 receptor were assessed by measuring [3H]arachidonic acid release and [Ca2+]i mobilization in Chinese hamster ovary cells transfected to express human ACE and B2 receptor, or in endothelial cells with constitutively expressed ACE and receptor. Administration of bradykinin or its ACE-resistant analogue desensitized the receptor, but it was resensitized (arachidonic acid release or [Ca2+]i mobilization) by agents such as enalaprilat (1 micromol/L). Enalaprilat was inactive in the absence of ACE expression. La3+ (100 micromol/L) inhibited the apparent resensitization, probably by blocking the entry of extracellular calcium. Enalaprilat resensitized the receptor via ACE to release arachidonic acid by bradykinin at a lower concentration (5 nmol/L) than required to mobilize [Ca2+]i (1 micromol/L). Monoclonal antibodies inhibiting the ACE N-domain active center and polyclonal antiserum potentiated bradykinin. The snake venom peptide BPP5a and metabolites of angiotensin and bradykinin (angiotensin-[1-9], angiotensin-[1-7], bradykinin-[1-8]; 1 micromol/L) enhanced arachidonic acid release by bradykinin. Angiotensin-(1-9) and -(1-7) also resensitized the receptor. Enalaprilat potentiated the bradykinin effect in cells expressing a mutant ACE with a single N-domain active site. Agents that reacted with a single active site, on the N-domain or on the C-domain, potentiated bradykinin not by blocking its inactivation but by inducing crosstalk between ACE and the receptor. Enalaprilat enhanced signaling via ACE by Galphai in lower concentration than by Galphaq-coupled receptor.

L3 ANSWER 11 OF 14 MEDLINE on STN  
ACCESSION NUMBER: 91277921 MEDLINE  
DOCUMENT NUMBER: PubMed ID: 2098549  
TITLE: Production of angiotensin-converting enzyme inhibitors from baker's yeast glyceraldehyde-3-phosphate dehydrogenase.  
AUTHOR: Kohama Y; Nagase Y; Oka H; Nakagawa T; Teramoto T; Murayama N; Tsujibo H; Inamori Y; Mimura T  
CORPORATE SOURCE: Faculty of Pharmaceutical Sciences, Osaka University, Japan.  
SOURCE: Journal of pharmacobio-dynamics, (1990 Dec) Vol. 13, No. 12, pp. 766-71.  
Journal code: 7901854. ISSN: 0386-846X.  
PUB. COUNTRY: Japan  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: Priority Journals  
ENTRY MONTH: 199108  
ENTRY DATE: Entered STN: 18 Aug 1991  
Last Updated on STN: 29 Jan 1999  
Entered Medline: 1 Aug 1991

AB Angiotensin-converting enzyme (ACE) inhibitors were excised from the molecule of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) preparation of baker's yeast by heating at 120 degrees C in 1 M AcOH-20 mM HCl. Three inhibitors were then purified by gel-permeation and reverse-phase chromatographies. One of the yeast ACE inhibitors, YG-3, was GAPDH peptide 79-89 (Pro-Ala-Asn-Leu-Pro-Trp-Gly-Ser-Asn-Val, IC50:18 microM), and contained the sequence homologous to vertebrate ACE inhibitors (GAPDH peptides 79-86 or 81-88). Other inhibitors, YG-1 (Gly-His-Lys-Ile-Ala-Thr-Phe-Gln-Glu-Arg, IC50: 0.4 microM) and YG-2

(Gly-Lys-Lys-Ile-Ala-Thr-Tyr-Gln-Glu-Arg, IC50: 2 microM), corresponded to amino acid residues 68-77 in two different forms of yeast GAPDH, respectively. Their sequences were quite different from those of the venom peptide family. YG-1 was the most potent ACE inhibitor among yeast and vertebrate GAPDH peptides excised by acid-limited proteolysis. Thus, yeast GAPDH seems to be an excellent source of naturally occurring ACE inhibitors.

L3 ANSWER 12 OF 14 MEDLINE on STN  
ACCESSION NUMBER: 91182410 MEDLINE  
DOCUMENT NUMBER: PubMed ID: 1368612  
TITLE: Bacillus stearothermophilus glyceraldehyde-3-phosphate dehydrogenase as a source of angiotensin-converting enzyme inhibitors.  
AUTHOR: Kohama Y; Nakagawa T; Oka H; Okuno Y; Mimura T; Tsujibo H; Inamori Y; Tsurutani R; Nagata K; Tomita K  
CORPORATE SOURCE: Faculty of Pharmaceutical Sciences, Osaka University, Japan.  
SOURCE: Agricultural and biological chemistry, (1990 Aug) Vol. 54, No. 8, pp. 2115-9.  
Journal code: 0370452. ISSN: 0002-1369.  
PUB. COUNTRY: Japan  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: Biotechnology  
ENTRY MONTH: 199105  
ENTRY DATE: Entered STN: 9 Aug 1995  
Last Updated on STN: 29 Jan 1999  
Entered Medline: 8 May 1991

AB The more potent inhibitory activity against angiotensin-converting enzyme (ACE) was excised from a glyceraldehyde-3-phosphate dehydrogenase (GAPDH) preparation of Bacillus stearothermophilus by heating at 120 degrees C in 1 M AcOH-20 mM HCl, as compared with GAPDH preparations of yeast and pig. Sufficient excision of B. stearothermophilus ACE inhibitors required a longer proteolysis time of 60 min. Two inhibitors were then purified by gel-permeation and reverse-phase chromatographies. One of the B. stearothermophilus ACE inhibitors BG-1, was the GAPDH peptide 68-77 (Gly-Lys-Glu-Ile-Ile-Val-Lys-Ala-Glu-Arg, IC50: 32 microM). Another inhibitor, BG-2 (Gly-Lys-Met-Val-Lys-Val-Val-Ser-Trp-Tyr, IC50: 6 microM), correspond to GAPDH peptide 304-313. These sequences were quite different from those of vertebrate GAPDH peptides and the venom peptide family with ACE inhibitory activity. BG-2 was found to be a non-competitive type inhibitor, differing from many natural peptide inhibitors. Thus, B. stearothermophilus GAPDH seemed to be a good source of new type ACE inhibitors, in addition to the advantages due to its thermophilic property.

L3 ANSWER 13 OF 14 MEDLINE on STN  
ACCESSION NUMBER: 89077785 MEDLINE  
DOCUMENT NUMBER: PubMed ID: 2849521  
TITLE: Evolution of angiotensin-converting enzyme inhibitors.  
AUTHOR: Wyvratt M J  
CORPORATE SOURCE: Merck Sharp & Dohme Research Laboratories, Rahway, N.J.  
SOURCE: Clinical physiology and biochemistry, (1988) Vol. 6, No. 3-4, pp. 217-29. Ref: 40  
Journal code: 8305885. ISSN: 0252-1164.  
PUB. COUNTRY: Switzerland  
DOCUMENT TYPE: (CLINICAL TRIAL)  
Journal; Article; (JOURNAL ARTICLE)  
General Review; (REVIEW)  
LANGUAGE: English  
FILE SEGMENT: Priority Journals

ENTRY MONTH: 198902  
ENTRY DATE: Entered STN: 8 Mar 1990  
Last Updated on STN: 8 Mar 1990  
Entered Medline: 9 Feb 1989

AB The renin-angiotensin system is perhaps the most important hormonal system in the regulation of blood pressure. Its influence on blood pressure is mediated by the potent vasoconstrictor angiotensin II. Since angiotensin-converting enzyme performs the last step in the biosynthesis of angiotensin II, inhibition of this enzyme has attracted the attention of many researchers as a novel approach in the control of high blood pressure. The evolution of inhibitors of this enzyme will be traced from the early snake venom peptide inhibitors to the drugs currently available for the treatment of high blood pressure and congestive heart failure.

L3 ANSWER 14 OF 14 MEDLINE on STN  
ACCESSION NUMBER: 82179297 MEDLINE  
DOCUMENT NUMBER: PubMed ID: 6176105  
TITLE: Development and design of specific inhibitors of angiotensin-converting enzyme.  
AUTHOR: Cushman D W; Cheung H S; Sabo E F; Ondetti M A  
SOURCE: The American journal of cardiology, (1982 Apr 21) Vol. 49, No. 6; pp. 1390-4.  
Journal code: 0207277. ISSN: 0002-9149.  
PUB. COUNTRY: United States  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals  
ENTRY MONTH: 198206  
ENTRY DATE: Entered STN: 17 Mar 1990  
Last Updated on STN: 17 Mar 1990  
Entered Medline: 24 Jun 1982

AB Captopril is a remarkably effective new antihypertensive drug designed and developed as a potent and specific inhibitor of angiotensin-converting enzyme, a zinc metalloproteinase that participates in the synthesis of a hypertensive peptide, angiotensin II, and in the degradation of a hypotensive peptide, bradykinin. Earlier studies with a snake venom peptide (teprotride or SQ 20881) that could be administered only by injection demonstrated that specific inhibitors of angiotensin-converting enzyme could be highly effective as antihypertensive drugs, and helped to clarify the specificity and mechanism of action of the enzyme. A hypothetical model of the active center of angiotensin-converting enzyme based on its presumed analogy to the well characterized zinc metalloproteinase carboxypeptidase A was used to guide logical sequential improvements of a weakly active prototype inhibitor that led eventually to the highly optimized structure of captopril. The hypothetical working model of the active site of angiotensin-converting enzyme used to develop captopril continues to provide a firm basis for development of new types of specific inhibitors of this biologically important enzyme.